Temozolomide and Gemcitabine hydrochloride drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Temozolomide (temozolomide) and Gemcitabine hydrochloride (gemcitabine hydrochloride). Common drug interactions include ascites among females and drug ineffective among males.

The phase IV clinical study analyzes what interactions people have when they take Temozolomide and Gemcitabine hydrochloride. It is created by eHealthMe based on reports of 25 people who take the same drugs from the FDA, and is updated regularly.

What is Temozolomide?

Temozolomide has active ingredients of temozolomide. It is often used in glioblastoma multiforme. eHealthMe is studying from 16,644 Temozolomide users. Check the latest studies of Temozolomide.

What is Gemcitabine hydrochloride?

Gemcitabine hydrochloride has active ingredients of gemcitabine hydrochloride. eHealthMe is studying from 14,775 Gemcitabine hydrochloride users. Check the latest studies of Gemcitabine hydrochloride.

On Jul, 06, 2026

25 people who take Temozolomide and Gemcitabine hydrochloride together, and have interactions are studied.

Temozolomide and Gemcitabine hydrochloride drug interactions.

What are the common drug interactions of Temozolomide and Gemcitabine Hydrochloride, by gender? *:

female:

Ascites (accumulation of fluid in the abdominal cavity)
Neoplasm progression (growth of tumour)
Malignant neoplasm progression (cancer tumour came back)
Desmoplastic small round cell tumour (soft tissue cancer)
Metastases to lymph nodes (cancer spreads to lymph node)
Metastases to liver (cancer spreads to liver)
Metastases to peritoneum (cancer spreads to peritoneum)
Breast cancer metastatic
Metastases to lung (cancer spreads to lung)
Disease progression

male:

Drug ineffective
Neutropenia (an abnormally low number of neutrophils)
Thrombocytopenia (decrease of platelets in blood)
Biliary sepsis
Desmoplastic small round cell tumour (soft tissue cancer)
Disease recurrence
Febrile neutropenia (fever with reduced white blood cells)
Haematotoxicity (toxins that destroy red blood cells)
Neoplasm progression (growth of tumour)
Prostatitis (inflammation of the prostate gland)

What are the common drug interactions of Temozolomide and Gemcitabine Hydrochloride, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Ascites (accumulation of fluid in the abdominal cavity)
Neoplasm progression (growth of tumour)
Malignant neoplasm progression (cancer tumour came back)
Desmoplastic small round cell tumour (soft tissue cancer)
Metastases to lymph nodes (cancer spreads to lymph node)
Metastases to liver (cancer spreads to liver)
Metastases to peritoneum (cancer spreads to peritoneum)
Disease progression
Bone marrow failure
Drug ineffective

20-29:

n/a

30-39:

Haematotoxicity (toxins that destroy red blood cells)
Neoplasm progression (growth of tumour)
Neutropenia (an abnormally low number of neutrophils)
Thrombocytopenia (decrease of platelets in blood)
Biliary sepsis
Desmoplastic small round cell tumour (soft tissue cancer)
Disease recurrence
Drug ineffective
Febrile neutropenia (fever with reduced white blood cells)

40-49:

Renal failure (kidney dysfunction)
Rhabdomyolysis (a condition in which damaged skeletal muscle tissue breaks down)

50-59:

n/a

60+:

Neutropenia (an abnormally low number of neutrophils)
Prostatitis (inflammation of the prostate gland)
Thrombocytopenia (decrease of platelets in blood)

What are the existing conditions these people have? *

Desmoplastic Small Round Cell Tumor: 20 people, 80.00%
Malignant Neoplasm Progression (cancer tumour came back): 3 people, 12.00%

* Approximation only. Some reports may have incomplete information.

Do you take Temozolomide and Gemcitabine hydrochloride?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously